Health Economics›Non-small cell lung cancer nonsquamous›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Non-small cell lung cancer nonsquamous · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel and Bevacizumab Variant #01	—	R 40 612	28d	5.4 mo	—	2	R 81 225 PFS proxy	1
Nintedanib and Pemetrexed Variant #01	—	R 20 530	21d	4.4 mo	—	2	R 41 060 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 16 002	28d	—	8.2 mo	2	R 32 005 PFS proxy	1
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	3.6 mo	—	6	R 79 350 PFS proxy	1
Gefitinib monotherapy Variant #01	—	R 4 278	28d	6.5 mo	—	2	R 8 556 PFS proxy	1
Docetaxel monotherapy Variant #02	—	R 2 921	28d	4.0 mo	10.6 mo	2	R 5 843 PFS proxy	3
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	12.2 mo	2	—	1

7 of 7 regimens shown